Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease-Reference-Cited by-同舟云学术

Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease

Published:2021-04-05 Issue:23 Volume:42 Page:2265-2269
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

ten Berg Jurrien¹²^ORCID,Sibbing Dirk³⁴⁵,Rocca Bianca⁶^ORCID,Van Belle Eric⁷,Chevalier Bernard⁸,Collet Jean-Philippe⁹^ORCID,Dudek Dariusz¹⁰¹¹,Gilard Martine¹²,Gorog Diana A¹³¹⁴^ORCID,Grapsa Julia¹⁵^ORCID,Grove Erik Lerkevang¹⁶^ORCID,Lancellotti Patrizio¹⁷¹⁸,Petronio Anna Sonia¹⁹,Rubboli Andrea²⁰,Torracca Lucia²¹,Vilahur Gemma²²,Witkowski Adam²³,Mehilli Julinda⁴⁵²⁴

Affiliation:

1. Department of Cardiology and Center for Platelet Function Research, St Antonius Hospital, Nieuwegein, the Netherlands

2. The Cardiovascular Research Institute Maastricht (CARIM), Maastricht, the Netherlands

3. Privatklinik Lauterbacher Mühle am Ostersee, Seeshaupt, Germany

4. Department of Cardiology, Ludwig-Maximilians-Universität München (LMU Munich), Munich, Germany

5. DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany

6. Institute of Pharmacology, Catholic University School of Medicine, Rome, Italy

7. Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, CHU Lille, Institut Coeur Poumon, Cardiology, INSERM U1011, Institut Pasteur de Lille, Lille, France

8. Ramsay Générale de Santé, ICPS, Hôpital Jacques Cartier, Massy, France

9. ACTION Study Group, Institut De Cardiologie, Hôpital Pitié-Salpêtrière (APHP), Sorbonne Université, Paris, France

10. Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland

11. Maria Cecilia Hospital, GVM Care&Research, Cotignola (RA), Italy

12. Department of Cardiology, La Cavale Blanche University Hospital Center, Optimization of Physiological Regulations, Science and Technical Training and Research Unit, University of Western Brittany, Brest, France

13. National Heart & Lung Institute, Imperial College, London, UK

14. Postgraduate Medical School, University of Hertfordshire, Hertfordshire, UK

15. Department of Cardiology, Guys and St Thomas NHS Hospitals, London, UK

16. Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark

17. University of Liège Hospital, GIGA Cardiovascular Sciences, Department of Cardiology, CHU Sart Tilman, Liège, Belgium

18. Gruppo Villa Maria Care and Research, Maria Cecilia Hospital, Cotignola, and Anthea Hospital, Bari, Italy

19. Department of Cardiology, University of Pisa, Pisa, Italy

20. Department of Cardiovascular Diseases-AUSL Romagna, Division of Cardiology, Ospedale S. Maria delle Croci, Ravenna, Italy

21. Department of Cardiac Surgery, Humanitas University Hospital Rozzano-Milano, Italy

22. Cardiovascular Program-ICCC, IR-Hospital de la Santa Creu i Sant Pau, CiberCV, Autonomous University of Barcelona, Spain

23. Department of Interventional Cardiology and Angiology, National Institute of Cardiology Cardiology, Warsaw, Poland

24. Department of Cardiology, Medizinische Klinik I, Landshut-Achdorf Hospital, Landshut, Germany

Abstract

Abstract Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/42/23/2265/38621831/ehab196.pdf

Reference15 articles.

1. 2017 ESC/EACTS Guidelines for the management of valvular heart disease;Baumgartner;Eur Heart J,2017

2. 2020 ACC/AHA Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Otto;Circulation,2021

3. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement;Dangas;N Engl J Med,2020

4. Anticoagulation with or without clopidogrel after transcatheter aortic-valve implantation;Nijenhuis;N Engl J Med,2020

5. Aspirin with or without clopidogrel after transcatheter aortic-valve implantation;Brouwer;N Engl J Med,2020

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chinese expert consensus on transfemoral transcatheter aortic valve replacement for pure aortic regurgitation (2023);Cardiology Plus;2024-08-01

2. Antithrombotic therapy for transcatheter structural heart intervention;EuroIntervention;2024-08

3. Importance of pseudoaneurysms after TAVI – a retrospective analysis of 2063 patients;Vasa;2024-07-17

4. Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation;Journal of Clinical Medicine;2024-06-21

5. Long-term prosthetic-associated subclinical thrombotic events evaluation by cardiac CTA after transcatheter aortic valve implantation: incidence and outcomes;Insights into Imaging;2024-05-30